Our company

What fuels our spirits every morning? We’re driven by a more sustainable future–a future where pressing environmental and social challenges are met with innovative, game-changing solutions. We’re driven by being on the brink of discovery, the chance to voyage into uncharted territory, grounded in our unwavering commitment to pioneering alternative solutions that can truly transform our world.


About us

We are a world-leading synthetic biology platform with a core mission to harness nature to drive bio-based, low-impact solutions to address the most pressing planetary issues through innovation & exploration. Founded in 2018, based on foundational research conducted at the Centre of Excellence in Synthetic Biology at The University of Copenhagen and the Novo Nordisk Foundation Centre for Biosustainability at The Technical University of Denmark, and driven by a responsible future where these pressing issues are met with transformative solutions. Grounded in a robust scientific foundation and unrivalled expertise in cell factory engineering, precision fermentation and enzymatic enhancement, we proudly unveil world-leading synthetic biology platforms, poised to transform entire industries for the betterment of society and the planet. We’re inspired by nature to protect nature.

Our Team

Our team, led by world-class scientists and inventors, is marked by diverse skills and expertise, as well as an unwavering commitment, forging a powerful team for driving change. This dynamic synergy fuels our pursuit of transformative advancements on our mission to reshape our world. With a proven history of successfully transitioning bio-based ingredients from the lab to commercialisation, our track record underscores our ability to turn innovative concepts into real-world solutions. This is our team pushing the boundaries of possibility.


Management Team

Nethaji is a world-renowned biochemist with expertise in bioengineering cells to produce high-value molecules. She was previously a research leader at the University of Copenhagen where she led multidisciplinary industrial collaboration on bio-based vanillin production from research to commercialisation. She was awarded University of Copenhagen PhD-Brain prize in 2011 and Business Prize in 2018 for exceptional achievements in research commercialisation through spinouts and industry collaborations. Nethaji has worked with world-leading synthetic biology companies and has a track record of high impact publications and patents.

Management Team

Nick is a highly experienced metabolic engineer and fermentation scientist with a successful track record developing innovative bio-based manufacturing methods to replace unsustainable synthetic chemical processes with numerous high-impact scientific publications and patents. Since receiving a PhD from the Technical University of Delft in The Netherlands Nick has spent his career in both academia (The Novo Nordisk Foundation Center for Biosustainability) and industry (Evolva) engineering micro-organisms to efficiently and sustainably produce valuable products ranging from bio-fuels to bio-plastics, flavour ingredients, nutraceuticals and pharmaceuticals. With a broad knowledge of synthetic biology techniques, and a specialization in fermentation development, Nick has successfully taken projects all the way from initial proof-of-concept to commercial scale production.

Management Team

Jan has been an executive finance professional for many years both as CFO in biotech companies – Gubra ApS. (privately held), NatImmune (Novo as controlling shareholder) and Neurokey (Novo as controlling shareholder) – and as Treasurer in a global company (Group 4 Falck A/S). In addition, he has held several senior positions in the financial sector primarily in investment banking and capital markets operations. He has two Graduate Diplomas in Business Administration from CBS. One in International Business and one in Organisation and Management.​

Management Team
Chief Business Officer

A recognized biotech executive with more than 20 years of management level industry experience. Throughout his career Emmanuel has worked in all areas of business development including sales, marketing, and general management successfully driving multiple revenue generation projects.

Management Team
Stephanie Michelle King
SVP Business Development

An experienced business development professional in the synbio industry, with 10+ years working in corporate and entrepreneurial environments. Her business development experience includes general management, marketing, sales, as well as business unit and innovation strategy. Her most recent position is VP of Business Development at London startup FabricNano, and prior to that she held a number of positions at Novozymes, including Head of Innovation for Future Fuels and Chemicals, and Business Portfolio Unit Lead for Water and Waste. Her industry experience, beyond synbio, includes biofuels and biochemicals, consumer health, water, carbon capture and utilization, and heterogeneous catalysis for production of ammonia, methanol, and syngas. Stephanie also holds a PhD in Environmental Chemistry from Harvard University and a Bachelors in Chemical Engineering from Rice University, giving her a strong analytical mindset for navigating the complexity of commercializing industrial biosolutions.


Chairman of the board, Independent board member

A founding partner of the Nordic Life Science Venture fund, Eir Ventures. Prior to launching Eir Ventures, Stephan was part of setting up Novo Seeds, the early stage company creation and investment arm of Novo Holdings. During his 12 years at Novo Seeds, he led creation and funding of more than 25 companies in Europe, with a particular focus on Scandinavia.

Independent board member

Claudia has an international legal background and 20 years’ experience from the Life Science industry, both as external and in-house legal counsel. She is specialised in R&D and business development related legal matters covering all types of commercial and R&D specific agreements, outsourcing and compliance aspects as well as complex research collaboration, partnerships and strategic licensing transactions with biotech, pharma companies and academia.

Representing the investors

Alex is a multicultural (Canada/France) engineer and experienced Venture Capitalist (traditional and corporate venture) with a demonstrated history of working in Cleantech (during the tough years from 2011-2016) and Deeptech with over 45 transactions under his belt. Skilled in Venture Capital, deal-making, developing early staged businesses into successful companies as well as performing exits and creating value for shareholders.

Akshat Kshetrapal
Board member representing DSM-Firmenich Ventures

Prior to joining DSM in 2020, Akshat sat on both sides of the table as an entrepreneur and investor. He started his entrepreneurial career by building WTEnergy, India's first carbon-trading platform and advisory services company, after which he embarked on his venture capital career at Sequoia Capital. Akshat has since gained extensive experience investing across the lifecycle of startups – with more than 45 investments totaling over 400 million euros and portfolio management for PGGM Private Equity, Max India, and Rockstart. At DSM, Akshat is responsible for investments in Europe and Israel in areas related to Nutrition, Health, and Biosciences. An Indian national currently living in Amsterdam, the Netherlands, Akshat holds an MBA from the Indian School of Business, and master’s degrees from the University of Amsterdam and the Delhi School of Economics.

Nethaji Gallage
Board member representing Founders

Nethaji is a world-renowned plant biochemist and synthetic biologist passionate about developing nature-inspired and sustainable solutions for various industries such as pharmaceuticals, consumer goods, bulk manufacturing and energy. She has worked with world-leading synthetic biology companies and has a track record of high impact publications and patents. She was previously a research group leader at the Center for Synthetic Biology at the University of Copenhagen where she developed biosynthetic production platforms for natural and novel cannabinoids, and previously led multidisciplinary research project on biosynthetic vanillin production from the lab to commercialization.

Jonas Ahm-Lundgren
Board observer representing The Footprint Firm

Jonas has 10+ years of investment, corporate finance, and strategy experience from both philanthropy, private equity and venture capital as well as from investment banking. Before joining The Footprint Firm, Jonas was Head of Strategy & Special Projects and member of the Senior Leadership Team in the Novo Nordisk Foundation, with responsibility for impact investments and philanthropic strategy in both health and sustainability. Also, Jonas served on the Investment Advisory Board of Den Sociale Kapitalfond Invest and has been involved in the corporate governance development of the Novo Nordisk Foundation group of companies. Prior to this Jonas worked at Novo Holdings, the Novo Nordisk Foundation’s investment company, covering an array of life science investments in sustainability, health and biotech companies, ranging from early start-ups to large mature companies in both the private and public space. Moreover, Jonas worked for a leading Danish M&A advisor FIH Partners, where he advised on a variety of transactions. Jonas holds a Master of Science in Applied Economics and Finance as well as a Bachelor of Science in International Business from Copenhagen Business School.


Professor of Psychopharmacology, Manchester University
Research fellow, Monash University
Professor of Plant Biochemistry, Copenhagen University
CEO, Klitgaard Epilepsy Consulting